Amgen Inc.(AMGN)Earnings, Financials & Key Ratios

AMGN•NASDAQ

$329.59

$177.87B mkt cap·23.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustrySpecialty and biologics-focused pharma

AboutAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Show more

Revenue$36.74B+9.9%
EBITDA$15.84B+23.3%
Net Income$7.71B+88.5%
EPS (Diluted)14.23+88.2%
Gross Margin70.8%+15.1%
EBITDA Margin43.12%+12.2%
Operating Margin29.06%+33.8%
Net Margin20.99%+71.5%
ROE106.1%+57.1%
ROIC14.81%+54.9%
Debt/Equity6.31-38.3%
Interest Coverage3.88+57.5%

Analysis→Technical→

AMGN Key Insights

Amgen Inc. (AMGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 103.1%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 22.0% free cash flow margin
✓15 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.9%

✗Weaknesses

✗High debt to equity ratio of 6.3x
✗Expensive at 20.6x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AMGN Price & Volume

Amgen Inc. (AMGN) stock price & volume — 10-year historical chart

Loading chart...

AMGN Growth Metrics

Amgen Inc. (AMGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years5.43%

5 Years7.64%

3 Years11.76%

TTM9.12%

Profit CAGR

10 Years1.06%

5 Years1.2%

3 Years5.58%

TTM31.47%

EPS CAGR

10 Years4.62%

5 Years2.94%

3 Years5.52%

TTM31.11%

Return on Capital

10 Years15.7%

5 Years14.56%

3 Years12.71%

Last Year15.95%

AMGN Recent Earnings

Amgen Inc. (AMGN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)

Q2 2026Latest

Apr 30, 2026

EPS

$5.15

Est $4.77

+8.0%

Revenue

$8.6B

Est $8.6B

+0.5%

Q1 2026

Feb 3, 2026

EPS

$5.29

Est $4.73

+11.8%

Revenue

$9.9B

Est $9.5B

+4.1%

Q4 2025

Nov 4, 2025

EPS

$5.64

Est $5.02

+12.4%

Revenue

$9.6B

Est $9.0B

+6.6%

Q3 2025

Aug 5, 2025

EPS

$6.02

Est $5.28

+14.0%

Revenue

$9.2B

Est $8.9B

+2.6%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$5.15vs $4.77+8.0%	$8.6Bvs $8.6B+0.5%
Q1 2026	Feb 3, 2026	$5.29vs $4.73+11.8%	$9.9Bvs $9.5B+4.1%
Q4 2025	Nov 4, 2025	$5.64vs $5.02+12.4%	$9.6Bvs $9.0B+6.6%
Q3 2025	Aug 5, 2025	$6.02vs $5.28+14.0%	$9.2Bvs $8.9B+2.6%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
GILDGilead Sciences, Inc.Direct Competitor	166.32B	133.48	351.26	6.04%	28.9%	37.62%	6.2%	1.39
BIIBBiogen Inc.Direct Competitor	27.92B	189.13	21.42	1.39%	13.92%	7.55%	7.34%	0.38
REGNRegeneron Pharmaceuticals, Inc.Direct Competitor	72.97B	702.33	16.93	0.99%	29.65%	14.32%	5.59%	0.09
VRTXVertex Pharmaceuticals IncorporatedDirect Competitor	107.94B	424.36	27.70	9.57%	35.4%	23.93%	2.96%	0.21
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
ABBVAbbVie Inc.Product Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
MRKMerck & Co., Inc.Product Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96

Compare AMGN vs Peers

Amgen Inc. (AMGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs GILD

Most directly comparable listed peer for AMGN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare AMGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs GILD, BIIB, REGN, VRTX

AMGN Income Statement

Amgen Inc. (AMGN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	22.85B	23.75B	23.36B	25.42B	25.98B	26.32B	28.19B	33.42B	36.74B	37.24B
Revenue Growth %	-0.62%	3.93%	-1.62%	8.83%	2.18%	1.32%	7.09%	18.57%	9.92%	9.12%
Cost of Goods Sold	4.07B	4.1B	4.36B	6.16B	6.45B	6.41B	8.41B	12.86B	10.73B	10.63B
COGS % of Revenue	17.81%	17.27%	18.65%	24.23%	24.84%	24.34%	29.85%	38.47%	29.2%	-
Gross Profit	18.78B▲ 0%	19.65B▲ 4.6%	19.01B▼ 3.3%	19.27B▲ 1.4%	19.52B▲ 1.3%	19.92B▲ 2.0%	19.77B▼ 0.7%	20.57B▲ 4.0%	26.01B▲ 26.5%	26.61B▲ 0%
Gross Margin %	82.19%	82.73%	81.35%	75.77%	75.16%	75.66%	70.15%	61.53%	70.8%	71.46%
Gross Profit Growth %	-0.26%	4.61%	-3.26%	1.36%	1.35%	2.01%	-0.71%	4%	26.48%	-
Operating Expenses	8.81B	9.38B	9.33B	10.13B	11.89B	10.35B	11.84B	13.31B	15.34B	14.83B
OpEx % of Revenue	38.54%	39.51%	39.95%	39.83%	45.75%	39.32%	42.01%	39.82%	41.74%	-
Selling, General & Admin	4.87B	5.33B	5.15B	5.73B	5.37B	5.41B	6.18B	7.1B	7.05B	6.95B
SG&A % of Revenue	21.31%	22.45%	22.04%	22.54%	20.66%	20.57%	21.92%	21.23%	19.19%	-
Research & Development	3.56B	3.74B	4.12B	4.21B	6.32B	4.43B	4.78B	5.96B	6.97B	7.51B
R&D % of Revenue	15.59%	15.74%	17.62%	16.55%	24.34%	16.84%	16.97%	17.84%	18.98%	-
Other Operating Expenses	375M	314M	66M	189M	194M	503M	879M	248M	1.31B	2M
Operating Income	9.97B▲ 0%	10.26B▲ 2.9%	9.67B▼ 5.7%	9.14B▼ 5.5%	7.64B▼ 16.4%	9.57B▲ 25.2%	7.9B▼ 17.4%	7.26B▼ 8.1%	10.68B▲ 47.1%	11.78B▲ 0%
Operating Margin %	43.65%	43.22%	41.41%	35.95%	29.4%	36.34%	28.01%	21.71%	29.06%	31.63%
Operating Income Growth %	1.83%	2.91%	-5.74%	-5.53%	-16.41%	25.23%	-17.45%	-8.09%	47.09%	-
EBITDA	11.93B	12.21B	11.88B	12.74B	11.04B	12.98B	11.97B	12.85B	15.84B	15.63B
EBITDA Margin %	52.2%	51.41%	50.85%	50.11%	42.48%	49.32%	42.45%	38.45%	43.12%	41.98%
EBITDA Growth %	0.24%	2.36%	-2.69%	7.24%	-13.37%	17.63%	-7.82%	7.37%	23.29%	20.02%
D&A (Non-Cash Add-back)	1.96B	1.95B	2.21B	3.6B	3.4B	3.42B	4.07B	5.59B	5.17B	3.78B
EBIT	10.9B	10.94B	10.43B	9.39B	7.9B	8.75B	10.73B	7.76B	10.68B	13.56B
Net Interest Income	-376M	-718M	-702M	-1.26B	-1.2B	-1.41B	-2.88B	-3.15B	-2.75B	-2.7B
Interest Income	928M	674M	587M	0	0	0	0	0	0	0
Interest Expense	1.3B	1.39B	1.29B	1.26B	1.2B	1.41B	2.88B	3.15B	2.75B	2.7B
Other Income/Expense	-376M	-718M	-536M	-1.01B	-938M	-2.22B	-42M	-2.65B	-1.7B	-2.69B
Pretax Income	9.6B▲ 0%	9.54B▼ 0.5%	9.14B▼ 4.3%	8.13B▼ 11.0%	6.7B▼ 17.6%	7.35B▲ 9.6%	7.86B▲ 6.9%	4.61B▼ 41.3%	8.98B▲ 94.7%	9.09B▲ 0%
Pretax Margin %	42%	40.19%	39.11%	31.99%	25.79%	27.91%	27.86%	13.79%	24.43%	24.4%
Income Tax	7.62B	1.15B	1.3B	869M	808M	794M	1.14B	519M	1.26B	1.29B
Effective Tax Rate %	79.38%	12.06%	14.18%	10.68%	12.06%	10.81%	14.49%	11.26%	14.09%	14.16%
Net Income	1.98B▲ 0%	8.39B▲ 324.2%	7.84B▼ 6.6%	7.26B▼ 7.4%	5.89B▼ 18.9%	6.55B▲ 11.2%	6.72B▲ 2.5%	4.09B▼ 39.1%	7.71B▲ 88.5%	7.8B▲ 0%
Net Margin %	8.66%	35.35%	33.57%	28.57%	22.68%	24.89%	23.83%	12.24%	20.99%	20.95%
Net Income Growth %	-74.37%	324.15%	-6.58%	-7.37%	-18.87%	11.18%	2.52%	-39.11%	88.53%	31.47%
Net Income (Continuing)	1.98B	8.39B	7.84B	7.26B	5.89B	6.55B	6.72B	4.09B	7.71B	7.8B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	2.69▲ 0%	12.62▲ 369.1%	12.88▲ 2.1%	12.31▼ 4.4%	10.28▼ 16.5%	12.11▲ 17.8%	12.49▲ 3.1%	7.56▼ 39.5%	14.23▲ 88.2%	14.34▲ 0%
EPS Growth %	-73.73%	369.15%	2.06%	-4.43%	-16.49%	17.8%	3.14%	-39.47%	88.23%	31.11%
EPS (Basic)	2.71	12.70	12.96	12.40	10.34	12.18	12.56	7.62	14.33	-
Diluted Shares Outstanding	735M	665M	609M	590M	573M	541M	538M	541M	542M	544M
Basic Shares Outstanding	731M	661M	605M	586M	570M	538M	535M	541M	538M	540M
Dividend Payout Ratio	170.04%	41.78%	44.75%	51.69%	68.1%	64.04%	67.83%	118.14%	66.45%	-

AMGN Balance Sheet

Amgen Inc. (AMGN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	49.48B	37.62B	18.44B	21.14B	19.39B	22.19B	30.33B	29.03B	29.06B	31.48B
Cash & Short-Term Investments	41.68B	29.3B	8.91B	10.65B	8.04B	9.3B	10.94B	11.97B	9.13B	12.04B
Cash Only	3.8B	6.95B	6.04B	6.27B	7.99B	7.63B	10.94B	11.97B	9.13B	12.04B
Short-Term Investments	37.88B	22.36B	2.87B	4.38B	48M	1.68B	0	0	0	0
Accounts Receivable	3.24B	3.58B	4.06B	4.53B	5.84B	6.39B	7.94B	7.5B	9.57B	9.14B
Days Sales Outstanding	51.71	55.03	63.39	64.96	82.04	88.63	102.83	81.91	95.07	87.97
Inventory	2.83B	2.94B	3.58B	3.89B	4.09B	4.93B	9.52B	7B	6.22B	6.19B
Days Inventory Outstanding	254.22	261.67	300.31	230.71	231.08	280.9	412.84	198.65	211.77	217.58
Other Current Assets	1.73B	1.79B	1.89B	2.08B	200M	355M	281M	419M	4.13B	4.11B
Total Non-Current Assets	30.48B	28.8B	41.27B	41.8B	41.78B	42.94B	66.82B	62.81B	61.53B	61.03B
Property, Plant & Equipment	4.99B	4.96B	4.93B	4.89B	5.18B	5.43B	5.94B	6.54B	7.91B	8.22B
Fixed Asset Turnover	4.58x	4.79x	4.74x	5.20x	5.01x	4.85x	4.74x	5.11x	4.64x	4.93x
Goodwill	14.76B	14.7B	14.7B	14.69B	14.89B	15.53B	18.63B	18.64B	18.68B	18.67B
Intangible Assets	8.61B	7.44B	19.41B	16.59B	15.18B	16.08B	32.64B	27.7B	22.28B	21.38B
Long-Term Investments	0	0	0	0	0	0	4.71B	5.36B	0	12.45B
Other Non-Current Assets	2.12B	1.7B	2.22B	5.64B	6.52B	5.9B	4.9B	4.58B	12.66B	37.21B
Total Assets	79.95B▲ 0%	66.42B▼ 16.9%	59.71B▼ 10.1%	62.95B▲ 5.4%	61.16B▼ 2.8%	65.12B▲ 6.5%	97.15B▲ 49.2%	91.84B▼ 5.5%	90.59B▼ 1.4%	92.5B▲ 0%
Asset Turnover	0.29x	0.36x	0.39x	0.40x	0.42x	0.40x	0.29x	0.36x	0.41x	0.41x
Asset Growth %	3%	-16.93%	-10.1%	5.43%	-2.83%	6.47%	49.19%	-5.47%	-1.36%	-1.98%
Total Current Liabilities	9.02B	13.49B	12.84B	11.65B	12.18B	15.69B	18.39B	23.1B	25.49B	24.95B
Accounts Payable	1.35B	1.21B	1.37B	1.42B	1.37B	1.57B	1.59B	1.91B	20.89B	0
Days Payables Outstanding	121.28	107.43	114.88	84.21	77.25	89.57	68.97	54.16	710.68	229.59
Short-Term Debt	1.15B	4.42B	2.95B	91M	87M	1.59B	1.44B	3.55B	4.6B	5.44B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.27B	1.54B	1.54B	1.57B	1.62B	1.1B	1.38B	1.33B	0	19.52B
Current Ratio	5.49x	2.79x	1.44x	1.81x	1.59x	1.41x	1.65x	1.26x	1.14x	1.14x
Quick Ratio	5.17x	2.57x	1.16x	1.48x	1.26x	1.10x	1.13x	0.95x	0.90x	0.90x
Cash Conversion Cycle	184.65	209.27	248.82	211.46	235.86	279.96	446.71	226.4	-403.83	75.96
Total Non-Current Liabilities	45.69B	40.43B	37.2B	41.89B	42.28B	45.77B	72.53B	62.86B	56.44B	58.36B
Long-Term Debt	34.19B	29.51B	26.95B	32.9B	33.22B	37.35B	63.17B	56.55B	50.01B	51.89B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	1.17B	864M	606M	0	0	11M	2.35B	1.62B	1.37B	5.55B
Other Non-Current Liabilities	10.34B	10.05B	9.64B	8.99B	9.06B	8.41B	7.01B	4.7B	5.07B	19.88B
Total Liabilities	54.71B	53.92B	50.03B	53.54B	54.47B	61.46B	90.92B	85.96B	81.93B	83.31B
Total Debt	35.34B	33.93B	29.9B	32.99B	33.31B	38.95B	64.61B	60.1B	54.6B	57.32B
Net Debt	31.54B	26.98B	23.87B	26.72B	25.32B	31.32B	53.67B	48.13B	45.48B	45.28B
Debt / Equity	1.40x	2.71x	3.09x	3.51x	4.97x	10.64x	10.37x	10.23x	6.31x	6.31x
Debt / EBITDA	2.96x	2.78x	2.52x	2.59x	3.02x	3.00x	5.40x	4.68x	3.45x	3.67x
Net Debt / EBITDA	2.64x	2.21x	2.01x	2.10x	2.29x	2.41x	4.48x	3.75x	2.87x	2.87x
Interest Coverage	8.36x	7.86x	8.09x	7.44x	6.60x	6.22x	3.73x	2.46x	3.88x	5.02x
Total Equity	25.24B▲ 0%	12.5B▼ 50.5%	9.67B▼ 22.6%	9.41B▼ 2.7%	6.7B▼ 28.8%	3.66B▼ 45.4%	6.23B▲ 70.2%	5.88B▼ 5.7%	8.66B▲ 47.3%	9.19B▲ 0%
Equity Growth %	-15.51%	-50.48%	-22.62%	-2.73%	-28.79%	-45.36%	70.23%	-5.7%	47.32%	148.54%
Book Value per Share	34.34	18.80	15.88	15.95	11.69	6.77	11.58	10.86	15.97	16.89
Total Shareholders' Equity	25.24B	12.5B	9.67B	9.41B	6.7B	3.66B	6.23B	5.88B	8.66B	9.19B
Common Stock	30.99B	31.25B	31.53B	31.8B	32.1B	32.51B	33.07B	33.53B	8.66B	0
Retained Earnings	-5.07B	-17.98B	-21.33B	-21.41B	-24.6B	-28.62B	-26.55B	-27.59B	0	0
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-679M	-769M	-528M	-985M	-796M	-231M	-289M	-66M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

AMGN Cash Flow Statement

Amgen Inc. (AMGN) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	11.18B	11.3B	9.15B	10.5B	9.26B	9.72B	8.47B	11.49B	9.96B	9.96B
Operating CF Margin %	48.92%	47.57%	39.17%	41.29%	35.65%	36.93%	30.05%	34.38%	27.1%	-
Operating CF Growth %	7.95%	1.06%	-19%	14.72%	-11.77%	4.97%	-12.86%	35.64%	-13.33%	14.86%
Net Income	1.98B	8.39B	7.84B	7.26B	5.89B	6.55B	6.72B	4.09B	7.71B	7.8B
Depreciation & Amortization	1.96B	1.95B	2.21B	3.6B	3.4B	3.42B	4.07B	5.59B	5.17B	3.78B
Stock-Based Compensation	329M	311M	308M	330M	341M	401M	431M	530M	0	284M
Deferred Taxes	-1.33B	-363M	-289M	-287M	-453M	-1.2B	-1.27B	-1.23B	-721M	-471M
Other Non-Cash Items	334M	386M	-186M	-195M	1.28B	1.28B	-991M	141M	-221M	325M
Working Capital Changes	7.91B	622M	-731M	-216M	-1.19B	-733M	-484M	2.37B	-1.98B	-962M
Change in Receivables	-58M	-378M	-504M	-427M	-429M	-746M	-1.01B	441M	-2.68B	-1.37B
Change in Inventory	133M	-3M	-66M	-215M	-165M	-742M	491M	2.53B	886M	598M
Change in Payables	424M	-143M	164M	45M	-69M	154M	-402M	312M	428M	-69M
Cash from Investing	-4.02B	14.34B	5.71B	-5.4B	733M	-6.04B	-26.2B	-1.05B	-1.94B	-2.21B
Capital Expenditures	-664M	-738M	-618M	-608M	-880M	-936M	-1.11B	-1.1B	-1.86B	-2.16B
CapEx % of Revenue	2.91%	3.11%	2.65%	2.39%	3.39%	3.56%	3.94%	3.28%	5.06%	-
Acquisitions	-19M	195M	-13.62B	-3.22B	-2.69B	-3.73B	-26.99B	0	-53M	-53M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-148M	-145M	-52M	-75M	-35M	-12M	225M	50M	-32M	0
Cash from Financing	-6.59B	-22.49B	-15.77B	-4.87B	-8.27B	-4.04B	21.05B	-9.41B	-10.86B	-5.32B
Debt Issued (Net)	71M	-1.12B	-4.51B	2.46B	795M	6.62B	25.68B	-4.26B	-5.68B	-2.88B
Equity Issued (Net)	-3.16B	-17.79B	-7.7B	-3.49B	-4.97B	-6.36B	0	-200M	0	0
Dividends Paid	-3.37B	-3.51B	-3.51B	-3.75B	-4.01B	-4.2B	-4.56B	-4.83B	-5.12B	-3.85B
Share Repurchases	-3.16B	-17.79B	-7.7B	-3.49B	-4.97B	-6.36B	0	-200M	0	0
Other Financing	-140M	-68M	-42M	-90M	-78M	-103M	-72M	-124M	-52M	1.41B
Net Change in Cash	559M▲ 0%	3.15B▲ 462.6%	-908M▼ 128.9%	229M▲ 125.2%	1.72B▲ 652.4%	-360M▼ 120.9%	3.31B▲ 1020.8%	1.03B▼ 69.0%	-2.84B▼ 376.4%	3.23B▲ 0%
Free Cash Flow	10.51B▲ 0%	10.56B▲ 0.4%	8.53B▼ 19.2%	9.89B▲ 15.9%	8.38B▼ 15.2%	8.79B▲ 4.8%	7.36B▼ 16.2%	10.39B▲ 41.2%	8.1B▼ 22.1%	8.6B▲ 0%
FCF Margin %	46.01%	44.46%	36.52%	38.9%	32.26%	33.37%	26.11%	31.1%	22.05%	23.09%
FCF Growth %	10.47%	0.43%	-19.19%	15.9%	-15.25%	4.82%	-16.23%	41.24%	-22.07%	-21.24%
FCF per Share	14.30	15.88	14.01	16.76	14.63	16.24	13.68	19.21	14.94	14.94
FCF Conversion (FCF/Net Income)	5.65x	1.35x	1.17x	1.45x	1.57x	1.48x	1.26x	2.81x	1.29x	1.10x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

AMGN Key Ratios

Amgen Inc. (AMGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.18%	44.48%	70.73%	76.13%	73.16%	126.47%	135.79%	67.55%	106.1%	89.41%
Return on Invested Capital (ROIC)	12.68%	15.99%	19.87%	19.68%	16.81%	21.42%	12.48%	9.56%	14.81%	14.81%
Gross Margin	82.19%	82.73%	81.35%	75.77%	75.16%	75.66%	70.15%	61.53%	70.8%	71.46%
Net Margin	8.66%	35.35%	33.57%	28.57%	22.68%	24.89%	23.83%	12.24%	20.99%	20.95%
Debt / Equity	1.40x	2.71x	3.09x	3.51x	4.97x	10.64x	10.37x	10.23x	6.31x	6.31x
Interest Coverage	8.36x	7.86x	8.09x	7.44x	6.60x	6.22x	3.73x	2.46x	3.88x	5.02x
FCF Conversion	5.65x	1.35x	1.17x	1.45x	1.57x	1.48x	1.26x	2.81x	1.29x	1.10x
Revenue Growth	-0.62%	3.93%	-1.62%	8.83%	2.18%	1.32%	7.09%	18.57%	9.92%	9.12%

AMGN SEC Filings & Documents

Amgen Inc. (AMGN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Apr 22, 2026·SEC

Material company update

Feb 19, 2026·SEC

10-K Annual Reports

FY 2026

Feb 13, 2026·SEC

FY 2025

Feb 14, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

FY 2025

May 2, 2025·SEC

AMGN Frequently Asked Questions

Amgen Inc. (AMGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Amgen Inc. (AMGN) reported $37.24B in revenue for fiscal year 2025. This represents a 1594% increase from $2.20B in 1996.

Amgen Inc. (AMGN) grew revenue by 9.9% over the past year. This is steady growth.

Yes, Amgen Inc. (AMGN) is profitable, generating $7.80B in net income for fiscal year 2025 (21.0% net margin).

Dividend & Returns

Yes, Amgen Inc. (AMGN) pays a dividend with a yield of 2.87%. This makes it attractive for income-focused investors.

Amgen Inc. (AMGN) has a return on equity (ROE) of 106.1%. This is excellent, indicating efficient use of shareholder capital.

Amgen Inc. (AMGN) generated $8.60B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AMGN

Amgen Inc. (AMGN) financial analysis — history, returns, DCA and operating performance tools

Full AMGN Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Amgen Inc.(AMGN)Earnings, Financials & Key Ratios

AMGN Key Insights

✓Strengths

✗Weaknesses

AMGN Price & Volume

AMGN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

AMGN Recent Earnings

AMGN Peer Comparison

Compare AMGN vs Peers

vs GILD

vs LLY

Compare Top 5

AMGN Income Statement

AMGN Balance Sheet

AMGN Cash Flow Statement

AMGN Key Ratios

AMGN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

AMGN Frequently Asked Questions

Explore More AMGN

Full AMGN Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation